New approaches in the treatment of metastatic transitional-cell cancer of the bladder.

Abstract

In recent years, chemotherapy of metastatic transitional-cell carcinoma of the bladder has advanced from the use of individual therapeutic agents, which has effected only rare responses, to the development of multi-agent regimens, which have greatly improved both partial and complete response rates, resulting in improved local care, palliation, and; perhaps, survival. However, because of the limited duration of response, frequent recurrences, and the significant proportion of patients with refractory disease, there have been only modest overall gains in long-term disease-free survival. These shortcomings have prompted investigation of alternative approaches to current combination chemotherapy regimens, including the use of hematopoietic growth factors and novel single-agent, multi-agent, and gene therapy protocols.

• Authors: D A Corral, C J Logothetis
• Journal: World journal of urology (World J Urol) Vol. 15 Issue 2 Pg. 139-43 ( 1997) ISSN: 0724-4983 [Print] Germany
• PMID: 9144905 (Publication Type: Journal Article, Review)

Chemical References

• Hematopoietic Cell Growth Factors
• Recombinant Proteins

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Transitional Cell (secondary, therapy)
• Genetic Therapy
• Hematopoietic Cell Growth Factors (therapeutic use)
• Humans
• Medical Oncology (methods)
• Recombinant Proteins
• Urinary Bladder Neoplasms (secondary, therapy)
• Urology (methods)